ERCC1表达与Ⅱ～ⅢA期鼻咽癌顺铂同期放化疗疗效的关系  

Relationship of ERCC1 expression and efficacy of cisplatin concurrent radiochemotherapy for patients with stageⅡ-ⅢA nasopharyngeal carcinoma

作　　者：陈绍俊[1] 杨慧[1] 吴梦馨 韦晓谋[3] 欧海玲[4] 以敏[5] 蒙以良[6] 林展[7] 黄海欣[1] 姚敏 CHEN Shaojun;YANG Hui;WU Mengxin(Department of Oncology ,Fourth Affiliated Hospital,Guangxi Medical University,Liuzhou 545005,CHINA)

机构地区：[1]广西医科大学第四附属医院肿瘤科,广西柳州545005 [2]江西上饶市人民医院肿瘤科 [3]广西医科大学第四附属医院肿瘤生物研究所,广西柳州545005 [4]广西中医药大学第一附属医院病理科 [5]广西医科大学第四附属医院病理科,广西柳州545005 [6]百色市人民医院肿瘤科 [7]玉林市第一人民医院放射肿瘤科 [8]美国凯斯西储大学梅赛德曼癌症中心放疗科

出　　处：《江苏医药》2019年第1期9-13,F0002,共6页Jiangsu Medical Journal

基　　金：柳州市科学研究与技术开发重点计划课题(2014J030404)

摘　　要：目的探讨切除修复交叉互补基因1(ERCC1)表达与Ⅱ～ⅢA期鼻咽癌顺铂同期放化疗疗效的关系。方法78例Ⅱ～ⅢA期鼻咽癌患者接受顺铂同期放化疗,检测鼻咽癌组织ERCC1蛋白和mRNA表达水平,分析ERCC1表达与疗效的关系。结果 ERCC1蛋白阳性表达率为46.15%,mRNA水平为0.456～1.412。78例患者中,完全缓解63例,部分缓解7例,病情稳定4例,疾病进展4例,有效率为89.74%,疾病控制率为94.87%。ERCC1蛋白阳性表达患者有效率为80.56%,低于ERCC1蛋白阴性表达患者的97.62%(P<0.05)。ERCC1mRNA低表达患者有效率为97.56%,高于ERCC1 mRNA高表达患者的81.08%(P<0.05)。78例患者1年生存率为98.72%,3年生存率为93.59%,5年生存率为91.03%。ERCC1蛋白阳性表达和阴性表达患者生存率比较无统计学差异(P>0.05),ERCC1mRNA高表达患者和低表达患者生存率比较亦无统计学差异(P>0.05)。结论 ERCC1的表达与Ⅱ～ⅢA期鼻咽癌患者顺铂同期放化疗疗效有关,但与患者生存率无关。Objective To investigate the relationship of excision repair cross complementary gene 1(ERCC1)expression and the efficacy of cisplatin concurrent radiochemotherapy for the patients with stageⅡ-ⅢA nasopharyngeal carcinoma.Methods A total of 78 cases with stageⅡ-ⅢA nasopharyngeal carcinoma was treated with cisplatin concurrent radiochemotherapy.The protein and mRNA expressions of ERCC1 were detected.The relationship of ERCC1 and the efficacy of cisplatin concurrent radiochemotherapy was analyzed.Results The protein positive expression of ERCC1 was46.15% and mRNA level was 0.456-1.412.Of 78 cases,63 cases were complete remission,7 cases were partial remission,4 cases were stable disease and 4 cases were progressive disease.The effectiveness rate and disease control rate were 89.74% and 94.87%,respectively.The effectiveness rate of the patients with protein positive expression and those with protein negative expression was significantly different(80.56% vs.97.62%)(P<0.05).The effectiveness rate of the patients with lower mRNA expression and those with higher mRNA expression was significantly different(97.56%vs.81.08%)(P<0.05).The 1-year,3-year and 5-year survival rates were 98.72%,93.59%and 91.03%,respectively,which were not related to the protein and mRNA expressions of ERCC1(P>0.05).Conclusion ERCC1 expression is related to the efficacy of cisplatin concurrent radiochemotherapy in the patients with stageⅡ-ⅢA nasopharyngeal carcinoma,which is not related to survival rate.

关 键 词：切除修复交叉互补基因1 鼻咽癌 顺铂 

分 类 号：R739[医药卫生—肿瘤]